Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther Ads (NQ: ADAP )

4.805 USD +0.085 (+1.80%)
Streaming Delayed Price Updated: 12:35 PM EDT, Apr 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Adaptimmune Ther Ads

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags ACRS NVCR DVAX
From Benzinga
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has started its SPEARHEAD-1 trial with ADP-A2M4 SPEAR T‑cells for patients with synovial sarcoma or myxoid/round... 
From GlobeNewswire News Releases
58 Biggest Movers From Yesterday
Gainers Peak Resorts, Inc. (NASDAQ: SKIS) shares jumped 112.8% to close at $10.85 on Monday after the company agreed to be ... 
Tags CADE BBIO GLYC
From Benzinga
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated a radiation sub-study of its ADP‑A2M4 trial in collaboration with the University of Texas MD... 
From GlobeNewswire News Releases
Look Under The Hood: BIB Has 29% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
These next-generation SPEAR T-cells may improve long term T-cell functions 
From GlobeNewswire News Releases
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
James Noble will transition to become a Non-Executive Director 
From GlobeNewswire News Releases
How The Pieces Add Up: KOMP Headed For $37
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
52 Biggest Movers From Yesterday
Gainers NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares surged 874.8 percent to close at $3.10 on Monday following news of luanch ... 
Tags NEPT Movers From Yesterday GLYC
From Benzinga
The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags CANF BCRX TBPH
From Benzinga
Biotechs That Successfully Combat Cancer Could See Blockbuster Returns
NetworkNewsWire Editorial Coverage 
From PR Newswire
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
- Adaptimmune to license Alpine’s Secreted and Transmembrane Immunomodulatory Protein technology for use with SPEAR T-cells to enhance antitumor responses - 
From GlobeNewswire News Releases
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
- Adaptimmune to license Alpine’s Secreted and Transmembrane Immunomodulatory Protein technology for use with SPEAR T-cells to enhance antitumor responses - 
From GlobeNewswire News Releases
Analysts Forecast 15% Upside For KOMP
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Benzinga's Top Upgrades, Downgrades For May 7, 2019
Top Upgrades JMP Securities upgraded Solaredge Technologies Inc (NASDAQ: SEDG) from Market Underperform to Market Outperform. ... 
Tags top upgrades Initiation Analyst Ratings
From Benzinga
Adaptimmune Reports First Quarter 2019 Financial Results
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2019. Adaptimmune shared a clinical update... 
From GlobeNewswire News Releases
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced significant clinical progress with partial responses in 4 out of 5 synovial sarcoma patients... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags IBB NVTR ATNX
From Benzinga
Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will present new and compelling data during an oral presentation about its off-the-shelf SPEAR T-cell program at... 
From GlobeNewswire News Releases
Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019. Following the... 
From GlobeNewswire News Releases
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks staged a recovery this week after being in the red in the previous two weeks. 
Tags Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks staged a recovery this week after being in the red in the previous two weeks. AbbVie Inc (NYSE: ABBV)'s psoriasis ... 
Tags ALDX Biotech HRTX
From Benzinga
55 Biggest Movers From Yesterday
Gainers Tiziana Life Sciences PLC (NASDAQ: TLSA) shares climbed 50.31 percent to close at $9.62 on Thursday. Travelzoo (NASDAQ: ... 
Tags CNSL News BCOV
From Benzinga
Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces an oral presentation by Dr. Jo Brewer, VP of Platform Sciences, summarizing data from Adaptimmune’s... 
From GlobeNewswire News Releases
Market Trends Toward New Normal in Smartsheet, Spok, TPG RE Finance Trust, DSP Group, Adaptimmune Therapeutics, and Aquestive Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Smartsheet Inc. (NYSE:SMAR),... 
From GlobeNewswire News Releases
55 Biggest Movers From Yesterday
Gainers Ocean Power Technologies, Inc. (NASDAQ: OPTT) shares gained 55.2 percent to close at $7.76 on Wednesday after the company ... 
Tags CEA ELF ZYNE
From Benzinga
Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from... 
From GlobeNewswire News Releases
Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting
- Preclinical data show that next generation SPEAR T-cells may improve long term T-cell functions as well as antitumor activity - 
From GlobeNewswire News Releases
Add Up The Pieces: KOMP Could Be Worth $36
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update
In a release issued under the same headline earlier today by Adaptimmune Therapeutics plc (Nasdaq:ADAP), please note that the third subheadline should read, "Treating patients in expansion phases of... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.